A Helpful Suite of Clinical Resources for Your Practice

Access clinical tools for use with patients as well as multimedia resources providing information on diagnosis of hepatic encephalopathy (HE) and reducing the risk of overt HE recurrence in adults with XIFAXAN.

Clinical Tools

Hepatic Encephalopathy Treatment Symptom Assessment Checklist

HE Symptom Assessment Checklist

A checklist for patients or caregivers to record common symptoms of hepatic encephalopathy. Share with your patients and/or caregivers prior to or at their visit to help them identify when to access immediate care or to facilitate a more productive discussion about their symptoms at their next appointment.

Download PDF >

Educational Resources

AASLD Guideline Recommendations on XIFAXAN for Overt Hepatic Encephalopathy

XIFAXAN and AASLD/EASL Hepatic Encephalopathy Practice Guidelines

A snapshot of the latest AASLD guidelines on the management of overt hepatic encephalopathy (HE). XIFAXAN earned AASLD/EASL’s highest possible recommendation* (GRADE I,A,1) as an add-on therapy to lactulose to reduce the risk of overt HE recurrence after a patient has a recurrence while on lactulose alone.1

Download PDF >
Patient Profile 62-Year-Old Female with Overt Hepatic Encephalopathy

Patient Profile: 62-Year-Old Female With Overt HE

Portrays a patient with cirrhosis diagnosed with an initial episode of overt hepatic encephalopathy (HE) when presenting to her gastroenterologist for routine monitoring; she subsequently presents with another overt HE episode. Consult this profile to help recognize patients for whom XIFAXAN may be an appropriate therapy.

Download PDF >
Patient Profile 58-Year-Old Male with Recurrent Overt Hepatic Encephalopathy

Patient Profile: 58-Year-Old Male With Recurrent Overt HE

A profile portraying a patient with cirrhosis diagnosed with recurrent overt hepatic encephalopathy (HE) when presenting to his gastroenterologist for routine monitoring. Consult this profile to help recognize patients for whom XIFAXAN may be an appropriate therapy.

Download PDF >

*Per the GRADE System for Evidence: Grade I=randomized, controlled trials; A=evidence is “high quality,” and further research is very unlikely to change our confidence in the estimated effect; and 1=recommendation is “strong,” with factors influencing strength of recommendation including the quality of evidence, presumed patient-important outcomes, and costs.1

XIFAXAN Quick Support & Access (QSA) Plugin and Order Set Kit

XIFAXAN Quick Support and Access

XIFAXAN Quick Support & Access (QSA) Plugin and Order Set Kit

Help standardize care within your workflow to help identify and manage patients living with overt hepatic encephalopathy. With the XIFAXAN QSA plugin, you can integrate important forms and resources into your organization’s workflow and have these resources at your fingertips.

Access XIFAXAN QSA

Clinical Tools

XIFAXAN Dosing for Overt Hepatic Encephalopathy

XIFAXAN Dosing for Overt HE

Review the recommended dosing for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for IBS-D in adults. Refer to this dual-indication card for general XIFAXAN dosing – includes the ICD-10 code* for overt HE.

Download PDF >
XIFAXAN Prior Authorization Road Map

XIFAXAN Prior Authorization Road Map

Step-by-step guide for completing prior authorization (PA) requirements for patients prescribed XIFAXAN, including common reasons for PA denials and guidance for Letters of Medical Necessity when needed. Download for guidance on PA requests, as well as information on electronic submissions with CoverMyMeds.

Download PDF >
XIFAXAN Treatment Savings Card

XIFAXAN Savings Card

Most eligible† patients with commercial insurance and coverage for XIFAXAN may pay as little as $0 for their XIFAXAN prescription. Maximum benefits and other restrictions apply.

Get savings card >

Educational Resources

Spotlight on Medication Adherence

Spotlight on Medication Adherence

Overview of the importance of medication adherence for patients receiving long-term therapy. Refer to this guide for helpful information when prescribing XIFAXAN for the reduction in risk of overt hepatic encephalopathy recurrence in adults.

Download PDF >
XIFAXAN Product Details

XIFAXAN Product Details

Core information on XIFAXAN for the treatment of IBS-D in adults and for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults. Provides an overview of HE, including screening criteria and the impact of overt HE on cognition and patients’ health. Core efficacy and safety data for XIFAXAN, recommended dosing and information on insurance coverage are also included. Obtain core product details about XIFAXAN in one informational brochure.

Download PDF >
XIFAXAN Treatment Savings Card

Help your eligible† patients save on XIFAXAN.

$0 for most eligible,† commercially insured patients with coverage for XIFAXAN. Maximum benefits and other restrictions apply.

Get Savings Card

Request Samples of XIFAXAN for Overt HE

*The ICD-10 Codes and all other patient-access-related information are provided for informational purposes only. It is the treating physician's responsibility to determine the proper diagnosis, treatment and applicable ICD-10 Code. Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.

†Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full cash-paying patients. Maximum benefits and other restrictions apply. Visit https://xifaxan.copaysavingsprogram.com/ or call 1-866-XIFAXAN for full eligibility criteria, terms and conditions.

American Academy of Physician Assistants (AAPA)
Visit website >
American Association for the Study of Liver Diseases (AASLD )
Visit website >
American Association of Nurse Practitioners (AANP)

Visit website >

American College of Gastroenterology (ACG) Advanced Practice Providers Resource Center

Visit website >

American Gastroenterological Association (AGA) NP/PA Resource Center

Visit website >

European Association for the Study of the Liver (EASL)
Visit website >
Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)
Visit website >
Society of Gastroenterology Nurses and Associates (SGNA)
Visit website >
World Gastroenterology Organisation (WGO)
Visit website >
INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN were:
    • HE (≥10%): Peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%), and ascites (11%)
    • IBS-D (≥2%): Nausea (3%), ALT increased (2%)
  • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

Reference: 1. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-735.

SEE MORE

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.